AI Transforms Drug Discovery And Precision Medicine

Precision medicine recently received a significant boost with the advent of new AI methods, from image analysis to foundation models to LLMs. These innovations enabled medical and biological data analysis to advance further how doctors tailor patients' treatment to their specific biological makeup. Furthermore, AI helps make medicine more personal at creation, reshaping drug development and design, enabling breakthroughs in target identification, and improving the efficacy of clinical trials.Founded in 2018 and headquartered in Tel-Aviv and Chicago, Nucleai is using AI to tackle spatial biology, a multidisciplinary field that studies the arrangement and interactions of biomolecules, cells, and tissues within a three-dimensional context. Initially focusing on oncology drug development, Nucleai’s integration of AI with spatial biology enables biomarker discovery and patient stratification at scale, directly contributing to better response rates in clinical trials, supporting tailored treatment strategies, and optimizing patient outcomes.